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Abstract: The discovery that breast cancers contain stem-like cells has fuelled exciting research 
in the last few years. These cells are referred to as breast cancer stem cells (BCSCs) and are 
thought to be involved in tumor initiation, progression, and metastasis. Being intrinsically 
resistant to chemo- and radiotherapy, they are also considered responsible for recurrence of the 
disease after treatment. BCSCs have been suggested to be at the basis of tumor complexity, as 
they have the ability to self-renew and give rise to highly proliferating and terminally differ-
entiated cancer cells that comprise the heterogeneous bulk of the tumor. There has been much 
speculation on the BCSC model, and in this review we address some fundamental questions, 
such as the identity of BCSCs and their involvement in tumor intra- and interheterogeneity. As 
an alternative to the BCSC model, we discuss clonal evolution, as both theories show extensive 
evidence in support of their arguments. Finally, we discuss a unifying idea that reconciles both 
models, which is based on stem cell plasticity and epigenetic modifications induced by the tumor 
microenvironment. The implications of cancer stem cell plasticity for drug discovery and future 
therapeutic interventions are presented.
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Breast cancer: a complex and heterogeneous 
disease
Breast cancer is one of the most common causes of cancer-related mortality in women 
worldwide (following lung cancer), with more than one million women diagnosed 
every year, and half a million dying from this disease. Although medical advances 
have contributed to early detection and better treatment, the mortality rate of women 
with breast cancer is still relatively high due to recurrence and metastasis.1 Breast 
cancer represents a major clinical challenge as it is a complex disease, and presents 
with significant variability in tissue histopathology, metastatic behavior, response to 
treatment, and patient outcomes. At a cellular level, breast cancer is regarded as a 
heterogeneous disease. This heterogeneity profoundly impacts treatment, as combina-
torial therapies are required to target different cancer cells. Heterogeneity is not only 
a feature of different breast tumor subtypes (interheterogeneity) but also of the same 
tumor (intraheterogeneity).2 In terms of interheterogeneity, different breast cancer 
subtypes can be classified based on clinical and histological factors, which include 
tumor grade, size, stage, and lymph node metastasis. According to the World Health 
Organization, there are at least 18 different histological subtypes of breast cancer.3 
Although these histological and clinical subsets give a detailed account of different 
tumors, there is still variability with grading and diagnosis.
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Molecular profiling of tumors shows that breast cancer 
is a heterogeneous set of different diseases, determined by 
various molecular alterations, rather than being a single dis-
ease with multiple manifestations.4 Genetic and epigenetic 
insults contribute to breast carcinogenesis.5 These altera-
tions cause aberrant expression of oncogenes and silencing 
of tumor suppressor genes with consequent disruption in 
gene networks regulating normal tissue homeostasis, such 
as cell proliferation, differentiation, motility, apoptosis, and 
growth.6 Gene expression profiling performed across breast 
cancer subsets identified estrogen receptor alpha (ER) posi-
tive (ER+) and negative (ER-) tumors as two distinct cancer 
types. Furthermore, it allowed further subclassification across 
five molecular subtypes depending on their “intrinsic gene 
expression” signature. These include normal-like, luminal 
A, luminal B, HER2 positive (HER2+), and basal-like sub-
types.7–9 Luminal A tumors are defined by the expression of 
both ER+ and/or progesterone receptors (PR+/PR-), and by 
the absence of HER2 amplification. Luminal B tumors are 
similar to luminal A, but include the amplification of HER2. 
HER2+ tumors are defined by HER2 expression and may 
lack the expression of ER and PR. Basal-like tumors are 
defined by the absence of ER, PR, and HER2 expressions 
and are further subdivided into basal A and basal B.7,10 More 
recently, a molecular signature identified as ‘claudin-low’ has 
been found to overlap with the basal B subtype. Claudin-low 
tumors lack the expression of ER, PR, and HER2, and are 
therefore also identified as “triple negative.” Normal-like 
breast cancer shows a gene signature similar to that of normal 
breast tissue.11 Less common than other subtypes, normal-
like cancers are of an ambiguous origin, and it is still debated 
whether they may represent breast tissue containing too few 
detectable cancer cells at the time of analysis.12
Breast cancer subtypes exhibit differences in the incidence 
of the disease, survival rates, and response to treatment. 
Luminal tumors (almost exclusively ER+) are the most 
common, and are associated with positive outcomes as they 
are treatable with hormonal therapy (tamoxifen). Luminal A 
subtypes are less proliferative than luminal B, and therefore 
have a better outcome. HER2+ tumors are highly prolifera-
tive, and present with worse outcomes even if treated with the 
anti-HER2 antibody trastuzumab (Herceptin®; Genentech 
USA, Inc, San Francisco, CA). Basal-like breast cancers 
represent high grade cancers with poor patient outcomes. 
Although somewhat sensitive to chemotherapy, these cancers 
are associated with high levels of recurrence after treatment. 
Targeted therapies, with the exception of poly (ADP-ribose) 
polymerase (PARP) inhibitors, are lacking for basal-like 
breast cancers (Table 1).13 New research has revealed that 
the complexity of breast cancer is higher than previously 
expected. Indeed, a screening of 2000 breast tumors that com-
bined inherited and acquired genetic alterations with gene 
expression data, highlighted a novel molecular stratification 
of tumors with ten different subtypes.14
The cellular origin of different breast tumor subtypes 
is still unclear. Some breast cancer subtypes have similar 
genetic and molecular compositions as their normal mam-
mary cell counterparts. For instance, luminal subtypes 
have a similar molecular makeup to luminal mature non-
clonogenic cells in that they are both ER+ and PR+. They 
also express characteristic luminal markers, such as CK18, 
CK19, CD24, MUC1, and ESA. In contrast, the basal B/
claudin-low subtypes lack the ER, PR, and HER2 expres-
sion and express markers characteristic of the basal lineage, 
such as CK14, CD49f, and CD44.15 This evidence would 
suggest that different cancer subtypes originate from either 
luminal or basal/myoepithelial progenitors within the nor-
mal tissue. However, this correlation does not exist when 
basal-like/BRCA1 mutant tumors are considered, as they 
seem to originate from luminal progenitor cells, rather 
than from basal progenitors.16,17 The origin of all tumor 
subtypes – whether it is a cell with multilineage potential, 
Table 1 Biological and clinical characteristics of breast cancer molecular subtypes
Subtype Markers Prevalence CSC enrichment Targeted treatment Mechanism Prognosis
Luminal A Mostly ER+ and/or PR+ 
(some HER2+)
42%–59% Low Tamoxifen ER Good
Luminal B Mostly ER+ and/or PR+ 
(some HER2+) 
Highly proliferative
6%–19% intermediate Tamoxifen, 
Herceptin
ER, 
HER2
intermediate
HER2+ HER2+ 
(can be ER+/ER- and PR+/PR-)
7%–12% High Lapatinib, 
Herceptin
HER2 Poor
Basal-like 
triple negative
Mostly ER-/PR-/HER2-,  
CK5+/6+, and/or HER1+
14%–20% High Bevacizumab, 
PARP inhibitors
HER1 Poor
Abbreviations: ER, estrogen receptor alpha; PR, progesterone receptor; HER2, epidermal growth factor receptor 2; HER1, epidermal growth factor receptor 1.
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a progenitor cell, or even a differentiated cell – is still under 
debate.  Moreover, this quest is further complicated by the 
occurrence of intratumor heterogeneity within breast cancer 
subtypes.  Intraheterogeneity is typically observed at the 
histological level, with different cell types and/or morpho-
logical appearances making up the bulk of the tumor. This 
is reflected in variable gene expression signatures and is best 
exemplified by the variable ER expression within a patient 
tumor.18 Two different models, supported by experimental 
findings, explain the origin of tumor heterogeneity: stem 
cell hierarchy and clonal evolution.
Breast cancer stem cells
The idea that cancer is driven by cells with stem cell-like 
features is not new, but has received renewed interest in 
recent years. The theory that cancer arises from stem cells was 
developed in the late nineteenth century when a correlation 
between embryonic stem cells and cancer was established 
among teratocarcinomas.19 The existence of malignant stem 
cells, also known as cancer stem cells (CSCs), was first 
discovered in acute myeloid leukemia; since then, CSCs have 
been identified and isolated in many solid tumors including 
breast, prostate, brain, and lung.20 According to the CSC 
hypothesis, the tumor is organized into aberrant hierarchies 
in which the CSC lies at the apex, and highly proliferating 
progenitors and terminally differentiated cancer cells reside at 
the bottom. In this model, CSCs would sustain tumor growth 
by symmetrical and asymmetrical self-renewal, whereas 
lineage-committed progenitor and differentiated cells would 
make up the heterogeneous bulk of the tumor (Figure1).
The CSC hierarchy model predicts that CSCs originate 
from the transformation of normal stem cells and, in this 
context, they are believed to be a rare population of cells 
more tumorigenic than the non-CSC population.20 However, 
the origin of CSC is at the center of controversy, as they may 
not necessarily derive from transformed stem cells, as the 
name implies. Therefore, many researchers prefer to refer to 
these cells as ‘cancer-initiating cells’ or ‘cancer-propagating 
cells.’ For the simplicity of semantics, we shall refer to them 
as CSCs in this review.21 The cell-of-origin of breast CSCs 
(BCSCs) is not yet known, but there are two possibilities: 
they either originate from undifferentiated mammary stem 
cells (MaSCs) or committed stem/progenitor cells through 
genetic and epigenetic reprogramming.21
The mammary gland is a very dynamic tissue and it is 
organized in a hierarchical fashion where MaSCs give rise 
to highly proliferating progenitors and differentiated cells of 
the epithelial and myoepithelial lineages (Figure 2). Most of 
our knowledge about MaSCs comes from the mouse model, 
where experiments of serial transplantation into the mam-
mary fat pad show that single basal stem cells, identified 
as CD49f+/CD29+/CD24low repopulating cells, can give rise 
to different mammary structural units.22,23 According to the 
BCSC theory, it is thought that long-living MaSCs might rep-
resent a likely target for malignant  transformation;  however, 
recent lineage-tracing experiments and clonal analyses have 
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Figure 1 Models explaining the origins of tumor heterogeneity in breast cancer.
Notes: Tumor heterogeneity (middle) is due to cancer cell types differing in genetic and phenotypic identities, as well as differing in terms of spatial and temporal existence 
within the tumor. These variations can depend on genetic insults and epigenetic alterations induced by microenvironmental changes. The two models explain the origin of this 
heterogeneity: the clonal evolution and the BCSC theory. The clonal evolution model (left) proposes that cancer clones compete with each other and the microenvironment 
to expand and dominate within the tumor (eg, Clone 1, 2, 3, and 4). Some clones may expand, but do not evolve fast enough to survive selective pressures and die off (Clone 5). 
A genetic drift of a single clone can generate a subclone (Clone 1.1). The BCSC model (right) proposes that BCSCs arise from transformed mammary cells. These BCSC 
self-renew (arced arrow), and give rise to highly proliferating progenitor cells that are responsible for generating differentiated cancer cells within the tumor.
Abbreviation: BCSC, breast cancer stem cell.
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defined the hierarchical structure of the mouse mammary 
gland and identified both luminal and myoepithelial long-
lived unipotent stem/progenitor cells as being able to clonally 
expand and maintain proliferation in adulthood.24 Therefore, 
these cells could also be a target for cellular transformation. 
Less is known about the organization of the human mammary 
gland and most of the data are inferred from experiments that 
combine flow cytometry, in vitro assays, and xenotransplan-
tation. Human MaSCs have been shown to have a CD49f+/
ESA-/low phenotype, suggesting a basal location of these cells 
in the gland;16,25 however, the precise structure of the human 
MaSCs hierarchy is still not fully understood. For instance, 
it is unclear whether MaSCs differentiate into a common 
bipotent progenitor that in turn gives rise to committed 
progenitors, especially since specific markers for such early 
lineages are currently lacking.26 Indeed, different studies have 
identified bipotent progenitor cells as luminal ESA+/CD49f+/
MUC1- or basal CD49f+/ESA-/low cell populations, suggesting 
that two different stem/progenitor cell populations could also 
exist in the human breast.26,27
BCSCs were first identified and isolated by the virtue of 
cell-surface expression markers, CD44 and ESA, and the 
absence of CD24.28 Cells identified as Lin-/ESA+/CD44+/
CD24-/low were found to be more tumorigenic compared 
to the CD44+/CD24+/ESA- cell population, and they were 
also able to generate tumors in non-obese diabetic/severe 
combine immunodeficient mice. Importantly, the transplanted 
tumors recapitulated the same heterogeneity of the original 
tumor, even after serial transplantation. The molecular char-
acterization of CD44+ and CD24+ cells also confirmed that 
CD44+ cells express basal stem cell markers, while CD24+ 
cells express markers characteristic of differentiated luminal 
cells.29 However, only a fraction of the CD44+/CD24-/low cells 
are highly tumorigenic, indicating that expression of these 
markers can be used to enrich BCSCs, but they may not 
identify a pure CSC population.30,31 In response, other breast 
cancer stem cell markers have been investigated. ALDH1 
has been shown to be a BCSC marker, and cancer cells that 
have a CD44+/CD24-/low/ALDH1high profile are more tumori-
genic, with as few as 20 cells being able to generate tumors 
after transplantation.32 However, ALDH1 activity has been 
shown to be low or absent in normal mammary stem cells, 
but high in luminal progenitor cells, again questioning the 
true identity of BCSCs.33
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Figure 2 Proposed model of the human MaSC differentiation hierarchy with corresponding surface markers for stem/progenitor cell identification and isolation.
Note: A possible relationship to the cellular origin of breast cancer subtypes is shown in Table 1.
Abbreviation: MaSC, mammary stem cell.
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BCSCs can also be enriched and cultured in non-adherent 
conditions through their ability to grow in suspension, 
bypassing anoikis and forming ‘mammospheres’.34 The 
generation of mammospheres can be used to measure the 
proliferative and the self-renewal abilities of BCSCs at 
clonal density, with stem and early progenitor cells forming 
a greater number of mammospheres compared to commit-
ted cells over the course of several generations. Importantly, 
mammosphere cultures enriched with undifferentiated cells 
demonstrated increased tumor-initiating capacity in vivo.30,35 
Mammospheres comprise a heterogeneous cell population 
and it is not known whether clonal sphere-forming cells 
represent stem/progenitor cells with basal characteristics, 
luminal characteristics, or both. An elegant study conducted 
by Pece et al identified normal mammary sphere-forming 
cells as quiescent MaSCs (which are high retainers of the 
PKH26 tracking dye), and these were found to be expressing 
CD24, DLL, DNER, and CD49f.36 PKH26high stem cells self-
renew asymmetrically giving rise to luminal or myoepithelial 
progenies. Importantly, cells with this molecular signature 
were found to be particularly enriched in poorly differentiated 
breast cancers.36 The frequency of BCSCs, characterized by 
the described markers, depends on the tumor subtype and 
histological grade, with high-grade tumors being the most 
enriched.37
It is now becoming evident that different breast cancer 
subtypes may have different cellular origins (Figure 2). 
Several studies have shown that primitive basal MaSCs are 
the likely cell of origin of basal B/claudin low and meta-
plastic cancers, whereas luminal progenitors can generate 
luminal and basal-like tumors. Indeed, transformation of 
luminal ESA+ progenitor cells by oncogene overexpression 
can give rise to both ER+ (luminal) and ER- (basal-like and 
possibly HER2+) cancers.12,15,16,38 Consistent with this notion 
are recent findings showing that luminal progenitors are the 
cell of origin for BRCA1 and TP53 mutated basal-like breast 
cancers.16,17,39
Controversies of the BCSC model
To date, in vivo xenograft and in vitro differentiation data 
suggest that the human mammary gland is organized in a 
hierarchical fashion, supporting the BCSC hypothesis.40 
However, the molecular identity of progenitor cells remains 
elusive, and it is therefore uncertain whether BCSCs represent 
transformed MaSCs, progenitor cells, or both. Recent lineage 
tracing experiments have shown how mouse skin, intestine, 
and brain CSCs initiate and sustain tumors in their own envi-
ronment.27,38,41 These studies, which elegantly demonstrate 
CSC activity in intact tumors, offer much promise for the 
CSC debate. Similar experiments conducted with BCSCs 
would greatly benefit our understanding of breast cancer even 
if the recapitulation of the human disease in mice remains 
a limitation.42 At present, transplantation into humanized 
mammary fat pads of immunocompromised mice is the 
best available assay for testing human BCSC function. It is 
thought that BCSCs are highly tumorigenic, with only a small 
number of cells required to form tumors when compared to 
non-stem cells.20
This assumption has been a subject of criticism. First, the 
tumorigenic behavior of cancer cells may vary probabilisti-
cally and, given optimal conditions, any tumor cell may have 
the same probability of exhibiting tumorigenic behavior.43 
Human tumor cells are not easily conducive to engraftment 
due to differences in the microenvironment of the mouse 
mammary fat pad.44 A second argument refers to the level 
of immunosuppression in some mouse models.45 A study 
by Quintana et al examining melanoma showed that the 
tumorigenicity of cancer cells can be dramatically increased 
by transplantation into non-obese diabetic/severe combine 
immunodeficient gamma mice, which is a mouse strain 
with superior immunodeficiency.46 This study suggests that 
putative BSCSs may be more tumorigenic simply because 
of preferential or improved engraftment ability.41
Since the initial publication by Al-Hajj et al, which identi-
fied BCSCs as a Lin-/ESA+/CD44+/CD24-/low (very similar to 
the CD49f+/ESA-/low/MUC1- phenotype), other studies have 
followed and they have identified BCSCs as being from the 
CD44+/CD24-/low population.28,29,47 However, the observation 
that luminal tumors contain a minimal or non-existent CD44+/
CD24- cell population, and the finding that CD44- cells are 
also tumorigenic in serial dilution transplantation, questions 
the true identity of BCSCs and creates doubt in that CD44+ 
cells may simply represent cells with better engraftment 
potential.31 Indeed, a degree of developmental plasticity has 
been observed in the BCSC hierarchy, whereby CD44+/CD24+ 
and CD44+/CD24- cells can interconvert into one another 
and can generate tumors after xenotransplantation.48 Interest-
ingly, the CD44+ cell signature is associated with a high risk 
of distant metastasis, even if metastatic lesions are enriched 
with luminal CD24+ cells.29 This indicates a phenotypic 
switch during tumor progression that is independent of the 
hierarchical differentiation program. This idea is consistent 
with the clinical observation that CD44+/CD24- cells are 
not correlated with breast cancer progression or prognosis, 
but favor distant metastasis.29 Therefore, the notion that the 
CD44+/CD24- phenotype represents a universal BCSCs 
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profile is somewhat simplistic, although basal cells identified 
by this profile seem to be the cell-of-origin of claudin-low/
basal B breast cancer.16
Another assumption of the stem cell hierarchy model 
is that BCSCs are a rare population of cells, but this may 
not necessarily be the case. Indeed, claudin-low, basal-like, 
and HER2+ cancers are highly enriched for BCSCs, and this 
characteristic is also retained in cancer cell lines derived 
from their respective primary tumors.12 The abundance of 
BCSCs is regulated by self-renewal mechanisms which are 
dependent on the function of the tumor suppressor gene TP53. 
Mutated or attenuated TP53 signaling confers symmetrical 
self-renewal, whereby cells can give rise to two identical 
BCSCs at each round of cell division. Under these conditions, 
the MaSC differentiation process is compromised and shifted 
towards an accumulation of undifferentiated BCSCs. Cell 
tracking experiments have proven symmetrical self-renewal 
in mammospheres generated from HER2+ transgenic mouse 
tumors and human basal cancer cell lines (personal obser-
vation).49 Altogether, this evidence casts some doubt on the 
BCSC hierarchy model, and it may explain why the BCSC 
hypothesis is not universally accepted by the scientific and 
medical communities. The key challenge of the BCSC model 
is the identification of the “primitive malignant stem cell” 
at the origin of different breast cancers, and recent evidence 
suggests that this model will need to evolve to accommodate 
stochastic events that contribute to inter- and intratumor 
phenotypic and genotypic heterogeneity. As an alternative, 
tumor heterogeneity can be explained by the clonal evolu-
tion model.
An alternative model: clonal 
evolution
In contrast to the stem cell hierarchy theory, the clonal evo-
lution model proposes that different clones of cancer cells 
arise with different selection pressures and microenvironment 
influences, which can include endogenous and exogenous 
 factors.50 Clones of transformed cells can accumulate 
when cellular hyperproliferation is combined with genetic 
 instability. In this way, tumor heterogeneity is caused by noise-
driven gene expression differences, as well as the growth of 
 transformed cells that do not necessarily involve stem cells.51 
Tumorigenesis is the result of a collection of random muta-
tions that are associated with the appearance of dominant 
cell clones with growth advantages resulting from activated 
oncogenes and/or inactivated tumor suppressor genes that 
are selected by a Darwinian process.52 The transformation 
of cells through genetic mutations is a stochastic process, 
whereby the phenotypic change in a cell is not predetermined; 
rather, the different cell clones are generated by random 
mutation hits. Through Darwinian selection, clones with 
advantageous mutations are selected to be dominant within 
the tissue, whereas disadvantageous mutations are discarded. 
The neutral clones are retained within the population caus-
ing a genetic drift. As a consequence, a selection of clones 
produces a dynamic state during cancer progression: some 
clones have no desirable mutations for further survival, while 
others have a selective advantage. Therefore, different parts 
of the tumor could be undergoing different selective pressure, 
owing to heterogeneity (Figure 1).53
When considering clonal heterogeneity, there is evidence 
that supports a close clonal relationship between the primary 
and metastatic tumors. However, in some tumors, metastatic 
spread occurs at the early stages of tumor evolution, hence 
the primary and metastatic tumors may evolve to have 
distinct genetic identities over time.53 The first report that 
investigated clonal diversity of breast tumors at the single 
cell level was published in 2011.54 This study reported the 
existence of punctuated clonal expansion with few persistent 
intermediates during tumor progression, rather than a gradual 
expansion of tumorigenic cells. A similar observation was 
recently reported in a study of next generation sequencing 
of 104 primary triple-negative breast cancer cases.55 At the 
time of diagnosis, these tumors displayed a wide spectrum 
of mutation heterogeneity and clonal evolution. Mutations 
in the TP53, PIK3CA, and PTEN genes seemed dominant 
compared to other genetic defects, but they were sometimes 
present at such low frequencies that they did not appear to 
be cancer founder mutations. Therefore, mutational het-
erogeneity is present at the onset of triple negative breast 
cancer, and patients present with either low-clonality or 
high-clonality cancers.
Clonal evolution can also explain the phenomenon 
of intertumor heterogeneity observed in different cancer 
 subtypes. One study that analyzed the contribution of germline 
and somatic alterations in a cohort of 2000 breast cancers 
revealed considerable tumor heterogeneity, and highlighted 
novel subtypes occurring with different frequencies in the 
population.14 However, genetic heterogeneity may not solely 
explain the phenotypic diversity of tumor cancer cells, as can-
cer cell behavior can also be influenced by the environment, 
which can alter gene expression by epigenetic modifications. 
The microenvironment is not homogenous in a tumor, as 
different regions within the tissue have varying densities of 
vasculature, different numbers and types of immune cells, 
and varying compositions of the extracellular matrix. Again, 
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on its own, the clonal evolution model may not fully explain 
the complexity of tumor heterogeneity as it needs to take in 
to account non-genetic (epigenetic) influences on hereditable 
phenotypes.
Stem cell plasticity and cancer:  
a unifying idea
It is becoming widely accepted that the BCSC and clonal evo-
lution models are not mutually exclusive; they both contribute 
to the explanation of tumor heterogeneity. A unifying idea 
is presented that discusses the role of the inherent develop-
mental plasticity of stem cells. Stochastic events that affect 
stem cell function – either genetic alterations or epigenetic 
modifications induced by the tumor microenvironment – can 
induce cellular transformation and confer cancer cells with 
stem cell-like characteristics. Although cell-lineage restric-
tion programs are established during embryonic development, 
adult stem cells maintain a degree of plasticity which is 
necessary for tissue repair and/or turnover.19 This flexibility 
is maintained by reversible epigenetic modifications which 
regulate gene expression in a cell-specific manner. Epigenetic 
modification of the chromatin regulates gene expression with-
out changing the DNA sequence. This is accomplished via 
DNA methylation, modification of histone tails, and modu-
lation by non-coding RNAs such as microRNA (miRNA).56 
With changes in chromatin conformation, epigenetic modi-
fications establish heritable transcriptional states responsible 
for the maintenance of cell identity and function. Epigenetic 
alterations are observed at the early stages of carcinogenesis, 
and they play a critical role in tumor initiation and CSC 
plasticity. Normal stem cells are vulnerable to epigenetic 
defects when induced to sustained self-renewal, resulting in 
silencing of tumor suppressor genes.57,58
Many tumor suppressor genes are developmentally 
regulated-genes that regulate the fate of stem cells. Their 
epigenetic silencing can generate CSCs locked in a self-
renewal state with impaired differentiation potential; indeed, 
several studies have shown that tumor suppressor genes are 
more likely to become silenced by DNA methylation in 
cancer.59–61 Reprogramming experiments have demonstrated 
that epigenetic landscapes are plastic and that they can be 
influenced and manipulated to change cell fate. The ability 
of stem cells, progenitor cells, or differentiated cells to 
transform into CSCs shows the intrinsic plasticity of these 
cells.19 Cells can acquire several rounds of carcinogenic 
insults before transformation, with progeny being susceptible 
to further insults, resulting in genetically and sometimes 
phenotypically different cancer cells.20 Since cellular and 
molecular phenotypes can be determined by genetic and 
epigenetic alterations affecting differentiation programs, 
it can be problematic to trace the cell-of-origin of different 
cancer types. Therefore, it is paramount to stress that the 
similarities of the genetic signatures between normal MaSCs 
and BCSCs do not necessarily reflect their direct association 
during transformation. For instance, BRCA1 and TP53 
mutations can affect the differentiation potential of luminal 
progenitor cells, leading to a basal tumor phenotype.16,17,39
Phenotypic switches in response to stochastic events, 
is one of the characteristics of CSCs. These involve the 
coexistence of different genetic and epigenetic states during 
cancer progression.19 BCSCs can shift between a stem cell 
and a non-stem cell state, owing to its plasticity. This was 
first identified in breast cancer cell lines where non-stem cells 
(CD44+/CD24+) were able to generate CD44+/CD24- BCSCs 
with tumorigenic properties and vice versa, depending upon 
activation of the Activin/Nodal pathway.48 One prediction of 
the stochastic and cell plasticity model is that the propor-
tion of cell populations in a given tumor is determined by a 
phenotypic equilibrium reached over time. Using Markov’s 
mathematical model, it has been shown that the change 
in the state of a cancerous cell is not predetermined by its 
previous cellular memory, but by its ability to maintaining 
equilibrium to reach a stable state. This is exemplified in 
breast cancer cell lines whereby BCSCs, luminal, and basal 
cells isolated according to the expression of a panel of cell 
surface markers, can change their phenotype over time into 
a metastable state. This metastable state is characterized by 
the same phenotype of the parental cell line, with luminal 
and basal committed cells each giving rise to a similar 
proportion of BCSCs of the parental cell line.62 Therefore, 
selective pressure could cause an interconversion of these 
cellular states, so that a metastable cell state is generated 
and dominates the tumor population. Consistent with this 
model, BCSCs could arise from more differentiated cells, 
following a bidirectional interconversion along the stem cell 
hierarchy.63 Based on this notion it is easy to reconcile how 
selective mutations that confer cancer cells with self-renewal 
ability can create dominant clones with BCSC characteristics 
during tumor progression. Different dominant clones could 
harbor distinct genetic alterations, and these could be selected 
independently under selective pressure (Figure 3).
Selective pressure can also take control of normal 
developmental processes and affect CSC plasticity.64 
Epithelial-to-mesenchymal transition (EMT) a reversible 
embryonic program that allows for a transition between 
cellular phenotypes during gastrulation, is recapitulated 
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during tumor progression and metastasis when cells change 
from an epithelial to a motile mesenchymal phenotype. 
Motile cancer cells can therefore invade neighboring and 
distant tissues and then colonize new sites after undergoing 
a reverse mesenchymal-to-epithelial transition (MET).20 
This interconversion explains the previously described 
plasticity of CD44+/CD24- cells, and the enrichment for 
CD24+ cells at the site of metastasis as cells undergo MET. 
EMT, induced by tumor microenvironment signals (TGFβ, 
Notch, EGF, Hedgehog, Wnt) induces BCSC properties, such 
as self-renewal and metastatic ability, in non-tumorigenic 
cells.65,66 TGFβ and other cytokines produced by the tumor 
microenvironment are directly involved in the epigenetic 
regulation of EMT, as well as in the acquisition of the BCSC 
phenotype. This effect is mediated by DNA methylation 
alterations that can cause silencing of adhesion molecules 
(eg, hypermethylation of CDH1 or E-Cadherin) and/or acti-
vation of EMT inducers by DNA hypomethylation.66 DNA 
methylation analysis of CD44+/CD24- cells isolated from 
neoplastic breast tissue shows hypomethylation of several 
transcription factors involved in EMT, including the tran-
scription factor FOXC1.67 TGFβ can also induce epigenetic 
silencing of miR-200a, a key microRNA (miRNA) involved 
in the regulation of EMT by inducing over-expression of 
the histone deacetylase SIRT1 and DNA methylation at the 
gene promoter region.
Two miRNA subfamilies, miR-200c/141 and miR-
200a/200b/429, are involved in the negative regulation of 
EMT, as they target EMT-inducing transcription factors 
ZEB1 and ZEB2.68 Both miR-200 gene cluster promoters are 
frequently hypermethylated, and the epigenetic silencing of 
miR-200c has been found in BCSCs.69 In addition, silencing 
of miRNAs negatively affects stem cell differentiation and 
induces self-renewal. This has been observed for miR200c 
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Figure 3 Unified theory of tumor heterogeneity.
Notes: The dynamic nature of tumor initiation and progression is characterized by genetic and epigenetic insults on putative cancer cells and the microenvironment. The 
heterogeneity of the microenvironment includes varying densities of extracellular matrix, vasculature, immune cells, and oxygen concentration that places selective pressure 
on cancer cells. The genetic and epigenetic make-up of cells within tumors will vary from one region to the other. Some regions may be characterized by a BCSC hierarchy 
(A), stochastic plasticity (B), and clonal evolution (C) simultaneously, increasing its complexity.
Abbreviations: BCSC, breast cancer stem cells; ECM, extracellular matrix.
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given that epigenetic silencing is associated with sustained 
expression of the stem cell self-renewal-regulating factors 
KLF4 and BMI1.69 Another example is the lethal-7 (let-7) 
gene, whose silencing is directly associated with a BCSC 
phenotype.70  The epigenetic silencing of let-7e mediated by 
the histone H3K4me3 demethylase JARID1B, over-expressed 
in breast cancer, contributes to cell cycle progression and 
the proliferation of cancer cells.71,72 Over-expression of 
other epigenetic modifiers can also induce BCSC plastic-
ity. For instance, high levels of the polycomb protein EZH2 
have been found in high grade breast cancers, and it plays a 
fundamental role in the regulation of stem cell self-renewal 
and differentiation.73,74
The type of epigenetic alterations involved in the genera-
tion of BCSCs may depend on their normal cell-of-origin, and 
therefore different cancer subtypes could acquire clonal char-
acteristics. This is demonstrated by the fact that transforma-
tion of genetically identical but phenotypically distinct breast 
epithelial cells can result in different cancer types.15,75
Can we target BCSC plasticity?  
The ultimate answer to the 
ultimate question
Tumor heterogeneity presents a major clinical problem. 
Important hurdles for successful treatment approaches 
include treating tumor subtypes with specific therapies and 
targeting elusive BCSCs. Breast cancer management involves 
a combination of surgery, chemotherapy, radiotherapy, and 
some targeted therapies such as hormonal therapy and the 
use of monoclonal antibodies.2 Although chemotherapy and 
radiotherapy are able to debulk the tumor mass, the majority 
of patients with basal or HER2+ cancer subtypes will relapse 
due to a minimal residual disease (MRD). BCSCs are directly 
implicated in MRD because of their intrinsic and extrinsic 
characteristics that are ultimately responsible for tumor recur-
rence.20 CSCs have an innate chemo- and radio-resistance 
due to the expression of drug transporters and detoxifying 
enzymes; altered DNA damage response mechanisms, such 
as resistance to apoptosis; enhanced DNA repair mechanisms; 
and quenching of reactive oxygen species.20 Stochastic events 
and adjuvant chemotherapy treatments can act as external 
factors that can generate resistant BCSCs clones. Such foci 
of surviving cells are subject to selective pressure and may 
lead to the development of complex drug resistance mecha-
nisms and increased aggressiveness of the resistant cells (it 
should be noted that drug resistance can involve endocrine 
therapies as well).76 Hormonal therapy fails to target ER- 
BCSCs, but they also induce the conversion of cancer cells 
to BCSCs.77 Since the adaptation and selection of different 
BCSC clones depend on cancer treatments, it is essential that 
future research efforts employ cancer patient stratification for 
more personalized treatment approaches.
Many studies are now focusing on targeting BCSC 
signaling pathways involved in stem cell self-renewal, such 
as Notch, Hedgehog, and Wnt; these have been extensively 
reviewed elsewhere.78–80 Other strategies have considered 
targeting EMT, which can be at the core of BCSC plasticity. 
Even if limited to the targeting of BCSCs with a basal phe-
notype, this strategy is of considerable interest;81 however, 
targeting of EMT on its own may not be a sufficient approach, 
as a crosstalk between embryonic signaling pathways exists. 
For instance, the TGFβ pathway, a main inducer of EMT, is 
known to interact with Wnt, Notch, and Hedgehog.78 There 
is also evidence that ER signaling influences EMT and the 
induction of BCSCs.77
The tumor microenvironment should also be consid-
ered for the development of BCSC-targeted therapies, 
and integrin-related signaling components, BCSC-surface 
markers, and stroma-secreted cytokines could be potential 
targets.82 The developmental plasticity of BCSCs as well as 
the reversible nature of the epigenetic alterations that regu-
late their function have led to the development of epigenetic 
therapies as new treatment options. Because epigenetic drugs 
can restore normal tissue homeostasis, they are a promising 
tool for differentiation therapy.83 The idea that BCSCs can 
be reset to their normal function via modification of their 
epigenetic landscape is a desired prospect. Tumorigenicity 
of breast cancer cells harboring genetic defects can be abol-
ished by epigenetic reprogramming, leading to reactivation of 
silenced tumor suppressor genes.84 Therefore, one can envi-
sion a therapeutic approach aimed at modulating dominant 
non-genetic defects to control stem cell function.
Epigenetic drugs that inhibit DNA methylation (DNMT 
inhibitors) and histone deacetylation (HDAC inhibitors) can 
restore the expression of silenced tumor suppressor genes, 
and these drugs are particularly effective for the treatment 
of leukemia. For instance, the DNA demethylating agent 
5-aza-2′-deoxycydine (AZA) has been shown to inhibit 
self-renewal of leukemic CSCs.85 In 2009, Stand Up to Cancer 
began testing epigenetic drugs on BCSCs and assessed their 
efficacy for the treatment of HER2+ and triple-negative breast 
cancer in clinical trials. Preclinical studies have shown that 
two demethylating agents, Decitabine and AZA at low and 
transient doses, induce the inhibition of BCSC growth as 
mammospheres due to a decrease in the CD44+/CD24-/
ALDH1+ stem cell population across breast cancer cell lines. 
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This treatment can also reduce the growth of patient-derived 
BCSC tumor xenografts due the underlying reactivation of 
tumor suppressor genes, and also due to the alteration of 
major cancer cell signaling pathways.86 These exciting results 
suggest that epigenetic therapies can become a reality as they 
can directly target BCSCs both in vitro and in vivo.
Conclusion
Breast cancer heterogeneity profoundly impacts the clini-
cal management of the disease. Because of the inter- and 
intraheterogeneity of breast tumors, classical and targeted 
therapies are not always successful in eradicating the disease, 
resulting in poor patient outcome. Cancer recurrence and 
metastasis are the main cause of poor patient survival, both of 
which are caused by expansion of MRD. Many studies have 
shown that tumor heterogeneity arises from BCSCs, whereas 
others have demonstrated that it is actually the result of clonal 
evolution. While BCSC and clonal evolution studies show 
extensive evidence in support of their arguments, caveats 
in both models still remain. A unified model based on stem 
cell plasticity can reconcile both views and account for clini-
cal and molecular characteristics of different breast tumor 
subtypes. According to the stem cell plasticity model, tumor 
progression is highly dynamic, with cancer cells constantly 
exposed to internal and external survival pressures. In this 
context, different areas of the tumor are affected differently 
by the microenvironment. Therefore, cells may be selected 
according to clonal evolution, stochastic plasticity, or accord-
ing to the BCSC differentiation hierarchy at different times 
and in different regions of the tumor (Figure 3).
Careful assessments of tumor heterogeneity and its 
microenvironment are therefore needed to devise targeted 
therapeutic strategies, as generalized interventions can result 
in the selection of the most resistant cancer cell population 
and recurrence of a more aggressive form of the disease. 
Cancer cell plasticity presents a clinical challenge, and future 
research should focus on understanding how to control its 
intrinsic and extrinsic effectors; this is certainly not an easy 
quest and novel avenues should be considered. In this light, 
epigenetic therapies may offer new solutions. By reversing 
the epigenetic landscape of cancer cells, epigenetic drugs can 
reset cancer cell plasticity and cause cancer cells to revert 
to normalcy. This approach might be instrumental as a new 
approach in the management of the disease, insofar as cancer 
could be treated as a chronic condition.
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